Wall Street Bullish on Immunovant as Analysts Hike Price Targets to $45

Key Facts

Reflecting growing confidence in the biotech sector, Immunovant shares received a string of positive evaluations from top Wall Street analysts. According to reports, BofA Securities, Wells Fargo, and H.C. Wainwright maintained their buy ratings for the stock, with updated price targets ranging between $40 and $45. These updates reflect analyst optimism following recent company developments, although Truist Financial remains at a neutral stance.

This positive outlook comes at a time of mixed movements in the healthcare sector, as investors monitor the performance of peers and financial partners. Compared to Wells Fargo (WFC), which is among the firms backing the stock, market data shows relative stability in the performance of major financial institutions during the current quarter. Per market data, analyst focus is currently centered on the ability of emerging biotech firms to achieve clinical breakthroughs that support these ambitious price targets.

Looking ahead, traders are awaiting key U.S. economic data that could impact risk appetite in the growth sector, primarily the Core PCE Price Index scheduled for release on May 28, 2026. Investors will also monitor liquidity levels with the release of GDP growth data on the same day, which could determine capital flows into biotech stocks like IMVT.US in the coming period.